Evidence map›Paper›PMID 16328927›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology

The effect of octreotide against oxidative damage in photosensitized conjunctiva and cornea of rabbits.

Ulkü Demir, Tamer Demir, Nusret Akpolat

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ulkü DemirDepartment of Ophthalmology, Medical Faculty, Firat University, 23119, Elaziğ, Turkey. ulkukohle@yahoo.com
Tamer Demir
Nusret Akpolat
Fırat University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to determine the protective effect of octreotide against oxidative damage in rabbit conjunctiva and cornea exposed to ultraviolet radiation. Twenty rabbits weighing 2,500-3,000 g were used and we divided them into 4 groups with randomly selected 5 rabbits. Rabbits were exposed to 2 J/cm(2)/h of ultraviolet A radiation (UVA) in the range 320-405 nm for 12 h per day for 90 days. Group 1 did not receive any treatment or UVA exposure (control group). Group 2 was only exposed to UVA radiation (UVA group). Group 3 received 8-methoxypsoralen and UVA (PUVA group). Group 4 was treated with 8-methoxypsoralen + UVA + octreotide (octreotide group). At the end of 90 days the rabbits were killed by decapitation and then eyes were enucleated. Both eyes of each rabbit were used for histopathologic evaluation. Histopathologic analysis of each group indicated that UVA group and PUVA group showed increasing edema (p<0.01), inflammation (p<0.05), fibroblast proliferation (p<0.05), dysplasia (p<0.05), hyperchromasia (p<0.01) in the conjunctiva. Octreotide group had significant protective effect in comparison with the UVA group and PUVA group. The UVA group and PUVA group showed increasing proliferation (p<0.01), dysplasia (p<0.01), hyperchromasia (p<0.01), pyknosis (p<0.001) and parakeratosis (p<0.01) in the corneal epithelium. Octreotide group showed similar results with control group. We conclude that octreotide which is considered as free radical scavenger protects the eye from the damaging effect of UV exposure.

Indexed as

AnimalsAntineoplastic Agents, HormonalCell ProliferationConjunctivaCorneaDisease Models, AnimalKeratoconjunctivitisMaleOctreotideOxidative StressRabbitsTreatment OutcomeUltraviolet RaysAntineoplastic Agents, HormonalOctreotide

Identifiers

PMID16328927
OpenAlexW1977521112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.